CD79A and infection: Two of these features (Env gp140–specific IgA and ADCP), which were not observed among top features in models of acquisition status, are intriguing as there is support for their potential biological relevance to protection from infection based on relationships with acquisition outcomes for the RV144 trial [22,34–38], which tested a different regimen in a different population, as well as in preclinical studies [39–41] that preceded the Mosaico (HVTN 706/HPX3002) and Imbokodo (HVTN 705/HPX2008) trials.